Hemcheck has received a first follow up order from its Finnish distributor
Hemcheck has received a first follow-up order from its Finnish distributor, Vingmed, which is also Hemcheck's distributor in Sweden and Norway. The order concerns s-Test and bgs-Test and is of minor economic value.
- It is very positive with a first follow-up order from Finland, which shows the activity in the market. We look forward to our continued cooperation with Vingmed in Finland, says Joen Averstad, acting CEO of Hemcheck.
For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, acting CEO
Tel: +46 76 108 8191
Email: [email protected]
About Hemcheck
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.
